SI-BONE, Inc.

NASDAQ:SIBN

Medical - Devices

Healthcare
$23.54 +3.45%

+$0.53 today

Market cap
$1.06B
Beta
0.70
P/E (TTM)
-41.4
EPS (TTM)
-$0.38
52W Low $11.48High $21.89

Volume 1.12M

Average 0.68M

SIBN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

SI-BONE, Inc.NASDAQ: SIBN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $4.19M fell 7.5% year over year, behind the +2.1% change in trailing-twelve-month research & development. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.

Context

  • Research & development amounted to 8.7% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -7.5% toward the trailing-twelve-month pace of +2.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.19M-3.9% QoQ
Last fiscal yearDec 2025
$17.45M+5.4% YoY
LTMMar 2026
$17.11M+2.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.5%——
1 year+5.4%——
3-year CAGR+8.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
17.45M USD
Year-over-year change
+5.4%
4-year CAGR
+8.8%

Research & Development vs competitors

How SIBN compares with its peers on the latest reported figures

  • SIBN's LTM Mar 2026 research & development of $17.11M is the lowest of the 6 companies compared; the peer median is $184.82M.
  • Its year-over-year change of +2.1% is the 4th highest of 6, against a peer median of +10.1%.
  • Research & development amounts to 8.3% of revenue for SIBN, versus a peer median of 5.9%.
SIBN Competitors Peer median
Research & Development for SIBN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$1.66B +10.1%+8.8%6.4%
SNNSmith & Nephew plcFY2025$346M +0.9%+0.1%5.6%
GMEDGlobus Medical, Inc.LTM Jun 2026$184.82M +30.3%+36.3%5.9%
ATECAlphatec Holdings, Inc.LTM Mar 2026$77.25M -2.6%+20.1%9.8%
CNMDCONMED CorporationLTM Mar 2026$59.27M +10.2%+5.8%4.3%
SIBNSI-BONE, Inc.LTM Mar 2026$17.11M +2.1%+8.6%8.3%
Peer median (excluding SIBN) $184.82M+10.1%+8.8%5.9%

Competitors are the stored peer set for SIBN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue90.15M106.41M138.89M167.18M200.93M
Cost of Revenue10.43M15.71M29.47M35.06M41.05M
Gross Profit79.72M90.7M109.42M132.12M159.88M
Gross Margin88.4%85.2%78.8%79.0%79.6%
Research & Development12.44M13.63M15.03M16.56M17.45M
Selling, General & Admin118.95M136.69M141.32M150.81M164.76M
Operating Expenses131.39M150.31M156.35M167.37M182.21M
Depreciation & Amortization2.09M3.45M5.43M4.38M2.72M
EBITDA(50.97M)(54.99M)(34.45M)(23.09M)(10.91M)
EBITDA Margin-56.5%-51.7%-24.8%-13.8%-5.4%
Operating Income(51.67M)(59.61M)(46.93M)(35.25M)(22.33M)
Operating Margin-57.3%-56.0%-33.8%-21.1%-11.1%
Interest Income186K1.3M6.92M7.85M6.07M
Interest Expense5.37M2.82M3.46M3.44M5.28M
Other Income / Expenses(4.9M)(1.65M)3.6M4.34M3.42M
Income Before Tax(56.57M)(61.26M)(43.34M)(30.91M)(18.91M)
Pre-Tax Margin-62.8%-57.6%-31.2%-18.5%-9.4%
Income Tax Expense00000
Net Income(56.57M)(61.26M)(43.34M)(30.91M)(18.91M)
Net Margin-62.8%-57.6%-31.2%-18.5%-9.4%
EPS (Basic)(1.71)(1.79)(1.13)(0.75)(0.44)
EPS (Diluted)(1.71)(1.79)(1.13)(0.75)(0.44)
Weighted Avg Shares33.15M34.2M38.43M41.47M43.51M
Weighted Avg Shares (Diluted)33.15M34.2M38.43M41.47M43.51M

SI-BONE, Inc.

NASDAQ:SIBN

Intrinsic Alpha fair value

Locked

Current Price

$23.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.